CONFERENCE PROCEEDING
The effect of highly absorbed curcumin on an oxidized LDL in patients with COPD
 
More details
Hide details
1
Division of Molecular Medicine, Graduate School of Pharmaceutical Science, University of Shizuoka, Shizuoka, Japan
2
Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan
CORRESPONDING AUTHOR
Masafumi Funamoto   

University of Shizuoka, Shizuoka, Japan
Publish date: 2019-10-12
 
Tob. Induc. Dis. 2019;17(Suppl 1):A35
KEYWORDS
ABSTRACT
Objective:
COPD is primarily caused by regular smoking and is associated with a high frequency of coronary artery disease. There is growing recognition that the inflammation in COPD is not only confined to the lungs but also involves the systemic circulation and can impact nonpulmonary organs, including blood vessels. α1-antitrypsin-low-density lipoprotein (AT-LDL) complex is an oxidized LDL that accelerates atherosclerosis. Curcumin, one of the best-investigated natural products, is a powerful antioxidant. However, the effects of curcumin on AT-LDL remain unknown. We hypothesized that Theracurmin®, a highly absorptive curcumin with improved bioavailability using a drug delivery system, ameliorates the inflammatory status in subjects with COPD.

Methods:
This is a randomized, double-blind, parallel-group study. The subjects were men or women (age, 20–85 years) who met the following criteria: 1) patients with COPD at stage 0, I, or II according to the definition by the Japanese Respiratory Society and 2) patients who have never smoked at least for the past 4 months. Subjects were randomly assigned to receive 90 mg Theracurmin® or placebo twice a day for 24 weeks, and changes in inflammatory parameters were evaluated.

Results:
There were no differences between the Theracurmin® and placebo groups in terms of age, male/female ratio, or body mass index in 39 evaluable subjects. The percent changes in blood pressure and hemoglobin A1c and LDL-cholesterol, triglyceride, or high-density lipoprotein-cholesterol levels after treatment were similar for the two groups. However, the percent change in the AT-LDL level was significantly (P=0.020) lower in the Theracurmin® group compared with the placebo group. However, LDL-C, IL-6 and TNF-α were not changed.

Conclusions:
Theracurmin® reduced levels of atherosclerotic AT-LDL, which may lead to the prevention of future cardiovascular events in patients with COPD.

eISSN:1617-9625